PureForm Global Inc, through its UK subsidiary PureForm International Ltd, has become the only UK CBD manufacturer to receive validation from the European Commission and the European Food Safety Authority for its Novel Food application.
As European authorities continue to introduce regulations to the CBD market place, PureForm CBD® is the first and only UK CBD manufacturing company producing CBD for sale as a raw ingredient to receive a Validated Novel Food Application from the European Food Safety Authority (EFSA).
This means that PureForm is in pole position to be amongst the first CBD companies in the world to be granted the much sought after Novel Food License in the EU.
The purpose of the Novel Food application is to ensure safety by way of clinical studies and compliance within the CBD industry so consumers can have access to safe CBD and purchase products with confidence.
Prior to Novel Foods Regulation, the CBD market had been a relatively poorly regulated sector. The validation of the PureForm CBD® dossier in the EU upholds its position as a leader in the market and goes beyond the industry standard.
Commenting on the validation of their dossier, COO of PureForm Global, Steve Miller said, “At a time when regulators are making it increasingly difficult for companies to import CBD into Europe, we are glad that our production facility in England will be able to supply both the UK and Europe with the highest quality CBD. The validation from the EFSA is a great boost for our clients and ourselves.”
PureForm CBD® is synthetically produced which means it exceeds the increasingly rigorous standards being required by the Home Office.
As explained by David McCormick, Head of European Operations, “Saying you have 0% THC (tetrahydrocannabinol) means nothing if you have only tested to parts per thousand.
We test to parts per million, meaning that even if the Home Office changes to a level of 0.001% THC, our product still meets this standard. This is an exciting first step. But during the second half of the year, we are looking forward to expanding our European offering to include both CBG and CBC, with five additional cannabinoids coming on stream in 2022. We intend to submit Novel Food applications for all of these in due course.
